Medtronic product linked to surgery problems
Wall Street Journal (subscription required), September 4, 2008
A potent substance used in spine-repair surgery to promote bone growth has been linked to life-threatening complications in dozens of patients. Many of the complications involving the product, Medtronic Inc.'s "Infuse Bone Graft," have occurred during off label uses. Medtronic representatives said it is taking the reports seriously and has been active in warning doctors of certain problems related to use of the bone graft. They added, however, that the rate of complications is low and that reports to the FDA of problems represent one-tenth of 1% of the units sold.
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- 3 Traits Personality Assessments Can't Reveal
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CHS Hacked, 4.5M Patient Records Compromised
- Business Roundup: M&A Activity Down Slightly in First Half of 2014
- CFO Exchange: Healthcare Leaders Share 5 Innovative Ideas
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- Large Employers Trimming Healthcare Spending